Literature DB >> 24080131

Smooth muscle cells from abdominal aortic aneurysms are unique and can independently and synergistically degrade insoluble elastin.

Nathan Airhart1, Bernard H Brownstein2, J Perren Cobb1, William Schierding3, Batool Arif1, Terri L Ennis1, Robert W Thompson4, John A Curci5.   

Abstract

BACKGROUND: The purpose of this study was to further elucidate the role of the vascular smooth muscle cells (SMCs) in abdominal aortic aneurysm (AAA) disease. We hypothesized that that AAA SMCs are unique and actively participate in the process of degrading the aortic matrix.
METHODS: Whole-genome expression profiles of SMCs from AAAs, nondilated abdominal aorta (NAA), and carotid endarterectomy (CEA) were compared. We quantified elastolytic activity by culturing SMCs in [(3)H]elastin-coated plates and measuring solubilized tritium in the media after 7 days. Matrix metalloproteinase (MMP)-2 and MMP-9 production was assessed using real-time polymerase chain reaction, zymography, and Western blotting.
RESULTS: Each SMC type exhibited a unique gene expression pattern. AAA SMCs had greater elastolytic activity than NAA-SMCs (+68%; P < .001) and CEA-SMCs (+45%; P < .001). Zymography showed an increase of active MMP-2 (62 kD) in media from AAA SMCs. AAA SMCs demonstrated twofold greater expression of MMP-2 messenger (m)RNA (P < .05) and 7.3-fold greater MMP-9 expression (P < .01) than NAA-SMCs. Culture with U937 monocytes caused a synergistic increase of elastolysis by AAA SMCs (41%; P < .001) but not NAA-SMCs or CEA-SMCs (P = .99). Coculture with U937 caused a large increase in MMP-9 mRNA in AAA-SMCs and NAA-SMCs (P < .001). MMP-2 mRNA expression was not affected. Western blots of culture media showed a fourfold increase of MMP-9 (92 kD) protein only in AAA-SMCs/U937 but not in NAA-SMCs/U937 (P < .001) and a large increase in active-MMP2 (62 kD), which was less apparent in NAA-SMCs/U937 media (P < .01).
CONCLUSIONS: AAA-SMCs have a unique gene expression profile and a proelastolytic phenotype that is augmented by macrophages. This may occur by a failure of post-transcriptional control of MMP-9 synthesis. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24080131      PMCID: PMC3968239          DOI: 10.1016/j.jvs.2013.07.097

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  34 in total

1.  Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms.

Authors:  Tom W G Carrell; Kevin G Burnand; Graham M A Wells; John M Clements; Alberto Smith
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Flow loading induces macrophage antioxidative gene expression in experimental aneurysms.

Authors:  Takeshi K Nakahashi; Katsuyuki Hoshina; Philip S Tsao; Eiketsu Sho; Mien Sho; John K Karwowski; Cory Yeh; Ruey-Bing Yang; James N Topper; Ronald L Dalman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-12-01       Impact factor: 8.311

3.  Aortic aneurysms as late sequelae of above-knee amputation.

Authors:  J F Vollmar; E Paes; P Pauschinger; E Henze; A Friesch
Journal:  Lancet       Date:  1989-10-07       Impact factor: 79.321

4.  Elastin degradation.

Authors:  M J Banda; Z Werb; J H McKerrow
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

5.  Examination of the apoptotic pathway and proteolysis in the pathogenesis of popliteal artery aneurysms.

Authors:  T Jacob; A Hingorani; E Ascher
Journal:  Eur J Vasc Endovasc Surg       Date:  2001-07       Impact factor: 7.069

6.  Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms.

Authors:  R Pyo; J K Lee; J M Shipley; J A Curci; D Mao; S J Ziporin; T L Ennis; S D Shapiro; R M Senior; R W Thompson
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

7.  Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting an immune-mediated response.

Authors:  A E Koch; G K Haines; R J Rizzo; J A Radosevich; R M Pope; P G Robinson; W H Pearce
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

8.  Differential regulation of matrix metalloproteinase activities in abdominal aortic aneurysms.

Authors:  Borhane Annabi; Daniel Shédid; Pierre Ghosn; Rhoda L Kenigsberg; Richard R Desrosiers; Michel W Bojanowski; Edith Beaulieu; Edgar Nassif; Robert Moumdjian; Richard Béliveau
Journal:  J Vasc Surg       Date:  2002-03       Impact factor: 4.268

9.  The prevalence and natural history of aortic aneurysms in heart and abdominal organ transplant patients.

Authors:  Michael J Englesbe; Audrey H Wu; Alexander W Clowes; R Eugene Zierler
Journal:  J Vasc Surg       Date:  2003-01       Impact factor: 4.268

10.  Inhibition of EP4 signaling attenuates aortic aneurysm formation.

Authors:  Utako Yokoyama; Ryo Ishiwata; Mei-Hua Jin; Yuko Kato; Orie Suzuki; Huiling Jin; Yasuhiro Ichikawa; Syun Kumagaya; Yuzo Katayama; Takayuki Fujita; Satoshi Okumura; Motohiko Sato; Yukihiko Sugimoto; Hiroki Aoki; Shinichi Suzuki; Munetaka Masuda; Susumu Minamisawa; Yoshihiro Ishikawa
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

View more
  28 in total

Review 1.  Understanding the pathogenesis of abdominal aortic aneurysms.

Authors:  Helena Kuivaniemi; Evan J Ryer; James R Elmore; Gerard Tromp
Journal:  Expert Rev Cardiovasc Ther       Date:  2015

2.  Vessel wall morphology is equivalent for different artery types and localizations of advanced human aneurysms.

Authors:  Albert Busch; Caroline Grimm; Elena Hartmann; Valentina Paloschi; Ralph Kickuth; Mariette Lengquist; Christoph Otto; Per Eriksson; Richard Kellersmann; Udo Lorenz; Lars Maegdefessel
Journal:  Histochem Cell Biol       Date:  2017-05-06       Impact factor: 4.304

3.  Periadventitial adipose-derived stem cell treatment halts elastase-induced abdominal aortic aneurysm progression.

Authors:  Kory J Blose; Terri L Ennis; Batool Arif; Justin S Weinbaum; John A Curci; David A Vorp
Journal:  Regen Med       Date:  2014       Impact factor: 3.806

4.  Nicotine-induced upregulation of VCAM-1, MMP-2, and MMP-9 through the α7-nAChR-JNK pathway in RAW264.7 and MOVAS cells.

Authors:  Zong-Zhuang Li; Zhen-Zhen Guo; Zhi Zhang; Qun-An Cao; Ya-Juan Zhu; Hua-Li Yao; Li-Li Wu; Qiu-Yan Dai
Journal:  Mol Cell Biochem       Date:  2014-11-09       Impact factor: 3.396

5.  Tamsulosin attenuates abdominal aortic aneurysm growth.

Authors:  William G Montgomery; Michael D Spinosa; J Michael Cullen; Morgan D Salmon; Gang Su; Taryn Hassinger; Ashish K Sharma; Guanyi Lu; Anna Fashandi; Gorav Ailawadi; Gilbert R Upchurch
Journal:  Surgery       Date:  2018-08-31       Impact factor: 3.982

6.  Aortic Aneurysm: In Defense of the Vascular Smooth Muscle Cell.

Authors:  Ha Won Kim; Neal L Weintraub
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-11       Impact factor: 8.311

7.  Targeted Gold Nanoparticles as an Indicator of Mechanical Damage in an Elastase Model of Aortic Aneurysm.

Authors:  Brooks A Lane; Xiaoying Wang; Susan M Lessner; Naren R Vyavahare; John F Eberth
Journal:  Ann Biomed Eng       Date:  2020-04-02       Impact factor: 3.934

Review 8.  Hereditary Influence in Thoracic Aortic Aneurysm and Dissection.

Authors:  Eric M Isselbacher; Christian Lacks Lino Cardenas; Mark E Lindsay
Journal:  Circulation       Date:  2016-06-14       Impact factor: 29.690

9.  Tryptophan-Derived 3-Hydroxyanthranilic Acid Contributes to Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Mice In Vivo.

Authors:  Qiongxin Wang; Ye Ding; Ping Song; Huaiping Zhu; Imoh Okon; Yang-Nan Ding; Hou-Zao Chen; De-Pei Liu; Ming-Hui Zou
Journal:  Circulation       Date:  2017-10-04       Impact factor: 29.690

10.  Murine abdominal aortic aneurysm model by orthotopic allograft transplantation of elastase-treated abdominal aorta.

Authors:  Zhenjie Liu; Qiwei Wang; Jun Ren; Carmel Rebecca Assa; Stephanie Morgan; Jasmine Giles; Qi Han; Bo Liu
Journal:  J Vasc Surg       Date:  2014-06-26       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.